|
|
Upfront Briefing
Intellia delivered the first-ever Phase 3 win for an in vivo CRISPR therapy: lonvo-z cut HAE attacks by 87% vs placebo, met every key secondary endpoint, and a rolling BLA is already in. Boehringer/Zealand also posted survodutide Phase 3 obesity topline at 16.6% weight loss after 76 weeks.
Elsewhere, Novartis reaffirmed FY 2026 guidance despite U.S. generic erosion, Ligand agreed to buy XOMA for $739M to bulk up its royalty book, and Seaport and Hemab launched IPOs targeting a combined ~$424M.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,173.9 |
+0.1% |
+2.8% |
| Nasdaq 100 |
27,305.7 |
0.0% |
+5.3% |
| Russell 2000 |
2,788.2 |
0.0% |
+4.6% |
| Healthcare (XLV) |
143.5 |
(0.5%) |
(7.3%) |
| Biotech (XBI) |
133.0 |
(0.2%) |
+3.5% |
| Nasdaq Biotech (NBI) |
5,872.8 |
(0.4%) |
(2.0%) |
| Clinical Trials (BBC) |
45.6 |
(0.8%) |
+6.5% |
|
- S&P 500 (+0.1%) and Nasdaq 100 (~flat) eked out fresh records as a Big Tech earnings week (Microsoft, Meta, Apple, Amazon all reporting) and the Fed meeting — with Powell potentially nearing his final meeting as chair if Kevin Warsh's nomination advances — kept positioning cautious; Brent above $96 on the Hormuz blockade added an inflation tail.
- Healthcare lagged on rotation, not fundamentals: XLV (0.5%), NBI (0.4%) and XBI (0.2%) finished red while money flowed into AI-led tech names; the move looked more like sector reweighting ahead of mega-cap prints than a biopharma-specific break.
- Higher-beta clinical-stage names took the most pain — Clinical Trials (BBC) (0.8%) — as investors trimmed catalyst risk into a heavy earnings, obesity-data and ASGCT/ESOC conference tape; Intellia's Phase 3 HAELO win came after the bell.
- Market data: U.S. close Mon 27-Apr-2026.
The Big 3
|
1
|
Intellia Phase 3 HAELO hits — first in vivo CRISPR Phase 3 win
|
- Intellia (NTLA) reported that a single 50 mg dose of lonvoguran ziclumeran (lonvo-z) cut monthly HAE attacks by 87% vs placebo (0.26 vs 2.10) over six months in the 80-patient HAELO trial, met all key secondary endpoints, and produced no serious adverse events in the lonvo-z arm. 62% of treated patients were both attack- and therapy-free over the efficacy window. Intellia initiated a rolling BLA with the FDA the same day, with submission targeted H2 2026 and a potential launch in H1 2027.
- Why it matters: This is the world's first Phase 3 success for any in vivo CRISPR therapy, validating the lipid-nanoparticle, liver-edit playbook beyond Casgevy's ex vivo proof point. The 87% attack reduction and prophylaxis-free profile reframe HAE — currently a recurring-injection market dominated by Takhzyro and Orladeyo — into a one-and-done category, with implications for KalVista's oral sebetralstat and BioCryst's berotralstat. For Intellia, the bigger optionality is the read-across to nex-z in ATTR-CM (MAGNITUDE Phase 3, off clinical hold) where the same delivery platform is in pivotal testing against Vertex/Alnylam economics.
- Source: PR
- More: BLA PR; BioCentury
|
|
2
|
Survodutide hits 16.6% weight loss in SYNCHRONIZE-1
|
- Boehringer Ingelheim and Zealand (ZEAL) reported that survodutide, a glucagon/GLP-1 dual agonist, delivered 16.6% mean weight loss after 76 weeks in the 725-patient SYNCHRONIZE-1 Phase 3 in obesity without T2D (17.8% on the efficacy estimand, vs 3.2% placebo). 85.1% of patients hit ≥5% weight loss vs 38.8% on placebo; the trial also reported waist-circumference and fat-mass benefits.
- Why it matters: 16.6% places survodutide ahead of Wegovy (~15%) but well below Zepbound (22.5% in SURMOUNT-1), CagriSema (~22.7%) and Lilly's retatrutide (~24%) — so the headline number alone won't make this a Lilly/Novo challenger. The investor case rests on (i) the glucagon arm's liver/MASH differentiation, with LIVERAGE Phase 3 in MASH and MASH-cirrhosis still to read out; and (ii) waist circumference and fat-mass benefits supporting a body-composition story. For Zealand, which is private-partner-only on this asset, the print de-risks high-single-to-low-double-digit royalties on global sales plus €315M of remaining milestones — meaningful at a $3.4B market cap. Boehringer is private, so all read-through goes through ZEAL.
- Source: PR
- More: Zealand PR
|
|
3
|
Novartis Q1 mixed; FY 2026 guidance reaffirmed
|
- Novartis (NVS) reported Q1 net sales down 5% at constant currency as U.S. Entresto generic erosion bit on schedule, but priority brands Kisqali, Pluvicto, Kesimpta, Scemblix and Leqvio kept growing. Management reaffirmed FY 2026 guidance and pointed to multiple H2 readouts that could underpin the mid- to long-term outlook.
- Why it matters: The reaffirmed guide is the signal — coming on the heels of the ~$12B Avidity close in H1 2026, which adds neuromuscular siRNA to the platform but also integration risk on top of the Entresto LOE. Holding the FY frame tells investors Novartis believes the priority-brand base, the Pluvicto rollout (despite the EU label-expansion withdrawal flagged Monday) and the Kisqali/Scemblix ramps are large enough to absorb both pressures while preserving capital-return optionality. With Roche, Sanofi and J&J already through Q1, NVS sits in line on growth but ahead on visibility into 2027.
- Source: PR
|
Everything Else that broke
- Biomea Fusion (BMEA) reports positive 52-week Phase 2 COVALENT-112 data in T1D showing C-peptide preservation after only 12 weeks of icovamenib dosing — small open-label dataset, value inflection lies in a controlled larger Phase 2. — PR
- Sobi Q1 2026 report cites strong execution, pipeline momentum. — PR
- Idorsia says QUVIVIQ sales rose 74% year over year in Q1. — PR
- Santhera cites positive AIFA reimbursement decision for AGAMREE. — PR
- Elanco products get emergency authorization vs New World screwworm. — PR
- Zentiva appeals EU court decision on urban wastewater directive. — PR
- Bioxodes to present final Phase 2a BIOX-101 ICH results at ESOC. — PR
- BioSpace: Garijo starts as Sanofi CEO, aims to ease Dupixent reliance. — BioSpace
- BioCentury: Intellia late-stage win tees up in vivo CRISPR test. — BioCentury
- BioCentury: new data suggest Oruka IL-23 mAb competitive in psoriasis. — BioCentury
- CARB-X awards $2.6M funding to AdJane for gonorrhea vaccine platform. — PR
- MediciNova highlights peer-reviewed immune-microenvironment target in brain mets. — PR
- Taysha to present new TSHA-102 construct-design data at ASGCT 2026. — PR
- Editas to present new preclinical data for EDIT-401 in hyperlipidemia. — PR
- Tessera to present sickle cell and in vivo CAR-T preclinical updates at ASGCT. — PR
- Arbor to present expansion of CNS editing platform capabilities at ASGCT. — PR
- ElevateBio to present nine ASGCT abstracts across gene editing platform. — PR
- Santhera reports full-year 2025 results. — PR
Deal Flow
M&A / BD&L
- Ligand agreed to acquire XOMA Royalty for about $739M in cash, adding more than 120 royalty-linked assets including seven marketed products and lifting Ligand's 2026 revenue and adjusted EPS outlook. — Reuters
- BioCentury Deals Report highlights Lilly's deal spree, including an Ajax takeout. — BioCentury
VC / Private Financings
- Fathom Therapeutics (formerly Atommap), a Boston-based AI protein-modeling biotech, announced an oversubscribed $47M Series A to scale its physics- and AI-enabled small-molecule discovery platform — led by Sutter Hill Ventures, with Chemistry, Alexandria Venture Investments and NY Ventures also participating. — PR
IPOs / Follow-Ons
- Seaport Therapeutics (SPTX, PureTech-incubated, run by Karuna co-founder Daphne Zohar) and Novo Nordisk Foundation–backed Hemab Therapeutics (COAG) launched U.S. IPOs targeting up to $212.4M and $211.8M respectively — a combined ~$424M raise that keeps the post-Kailera listing window open into May. Goldman Sachs is on both books. — Reuters
Academic Corner - The arrival of digital twins and in silico trials in drug development. — Nature Medicine
- Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial. — Nature Medicine
- The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond. — Nature RDD
- Mechanistic design of cell-penetrating disruptors for phospho-dependent TACC3-CHC interaction. — Cell
|
|
That’s it — may your toplines be lean, your royalty streams be accretive and your guidance be boring in exactly the right way. See you tomorrow. BioBucks Team
|
|
|
